Posted by Michael Wonder on 03 May 2026
Incyte announces FDA Approval of Jakafi XR (ruxolitinib) extended release tablets for the treatment of myelofibrosis, polycythemia vera and graft versus host disease
1 May 2026 - Jakafi XR will be available for pharmacy orders by 8 May 2026.
Incyte today announced that the US FDA has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediate or high risk myelofibrosis; adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft versus host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy.
